Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Molecular basis for the phenotypical diversity of phenylketonuria and related hyperphenylalaninaemias

Conclusion

Phenylalanine hydroxylase deficiency results in a fairly continuous spectrum of metabolic phenotypes, which can now be predicted by means of molecular analysis. Methods for direct detection of previously identified mutations and mutation scanning techniques (SSCP and DGGE) have facilitated genotyping of the hyperphenylalaninaemic neonate. Genotyping will confirm that the hyperphenylalaninaemic neonate has PAH deficiency and not a BH4-deficient form of hyperphenylalaninaemia or acquired hyperphenylalaninaemia. Genotyping will also distinguish between non-PKU HPA neonates and PKU patients. Finally, genotyping predicts the metabolic phenotype, facilitating optimal dietary therapy from the neonatal period.

A possible relationship between mutation genotype and the ultimate prognosis of PKU (MRI changes, cognitive development), and the question of whether the maternal genotype and the mutant allele of her offspring may influence pregnancy outcome are challenges for future studies.

This is a preview of subscription content, log in to check access.

References

  1. DiLella AG, Huang WM, Woo SLC (1988) Screening for phenylketonuria mutations by DNA amplification with polymerase chain reaction.Lancet 1: 497–499.

  2. Economou-Petersen E, Henriksen KF, Guldberg P, Güttler F (1992) Molecular basis for nonphenylketonuria hyperphenylalaninemia.Genomics 14: 1–5.

  3. Guldberg P, Güttler F (1992) PCR in the diagnosis of phenylketonuria.Ann Med 24: 187–190.

  4. Güttler F (1980) Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood.Acta Paediatr Scand 280 (suppl): 1–80.

  5. Güttler F, Lou H (1990) Phenylketonuria and hyperphenylalaninemia. In Fernandes J, Saudubray JM, Tada K, eds.Inborn Metabolic Disease: Diagnosis and Treatment. Berlin, Heidelberg: Springer Verlag, 161–174.

  6. Güttler F, Woo SLC (1986) Molecular genetics of PKU.J Inher Metab Dis 9 (suppl): 58–68.

  7. Okano Y, Eisensmith RC, Güttler F et al (1991) Molecular basis of phenotypic heterogeneity in phenylketonuria.N Engl J Med 324: 1232–1238.

  8. Scriver CR, Kaufman S, Woo SLC (1989) The hyperphenylalaninemias. In Scriver CR, Beaudet A, Sly W, Valle D, eds.The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 495–546.

  9. Ten Kate LP (1990) Carrier screening of cystic fibrosis and other autosomal recessive diseases.Am J Hum Genet 47: 359–361.

  10. Wong C, Dowling CE, Saiki RK, Higuchi RG, Erlich HA, Kazazian HH Jr (1987) Characterization of β-thalassemia mutations using direct genomic sequencing of amplified single copy DNA.Nature 330: 384–386.

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Güttler, F., Guldberg, P., Henriksen, K.F. et al. Molecular basis for the phenotypical diversity of phenylketonuria and related hyperphenylalaninaemias. J Inherit Metab Dis 16, 602–604 (1993). https://doi.org/10.1007/BF00711693

Download citation

Keywords

  • Phenylalanine
  • Pregnancy Outcome
  • Direct Detection
  • Phenylketonuria
  • Metabolic Phenotype